Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
81 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Cubist Pharmaceuticals, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Cubist Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Cubist Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Cubist Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Cubist Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Cubist Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Cubist Pharmaceuticals, Inc.'s pipeline products Reasons to buy - Evaluate Cubist Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Cubist Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Cubist Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Cubist Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cubist Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Cubist Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Cubist Pharmaceuticals, Inc. Snapshot 6 Cubist Pharmaceuticals, Inc. Overview 6 Key Information 6 Key Facts 6 Cubist Pharmaceuticals, Inc. - Research and Development Overview 7 Key Therapeutic Areas 7 Cubist Pharmaceuticals, Inc. - Pipeline Review 11 Pipeline Products by Stage of Development 11 Pipeline Products - Monotherapy 12 Pipeline Products - Combination Treatment Modalities 13 Pipeline Products - Partnered Products 14 Partnered Products/Combination Treatment Modalities 15 Cubist Pharmaceuticals, Inc. - Pipeline Products Glance 16 Cubist Pharmaceuticals, Inc. - Late Stage Pipeline Products 16 Pre-Registration Products/Combination Treatment Modalities 16 Phase III Products/Combination Treatment Modalities 17 Cubist Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 18 Phase II Products/Combination Treatment Modalities 18 Phase I Products/Combination Treatment Modalities 19 Cubist Pharmaceuticals, Inc. - Early Stage Pipeline Products 20 Preclinical Products/Combination Treatment Modalities 20 Discovery Products/Combination Treatment Modalities 21 Cubist Pharmaceuticals, Inc. - Drug Profiles 22 (ceftolozane + tazobactam) 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 tedizolid phosphate 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 bevenopran 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 fidaxomicin 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 solithromycin 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 surotomycin 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 CB-618 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 CB-027 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 GP-4 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Small Molecule to Inhibit DHFR for Bacterial Infections 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Small Molecules for Bacterial Infections 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Undisclosed Drug Targeting GPCRs 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Cubist Pharmaceuticals, Inc. - Pipeline Analysis 40 Cubist Pharmaceuticals, Inc. - Pipeline Products by Target 40 Cubist Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 42 Cubist Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 43 Cubist Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 44 Cubist Pharmaceuticals, Inc. - Recent Pipeline Updates 46 Cubist Pharmaceuticals, Inc. - Dormant Projects 73 Cubist Pharmaceuticals, Inc. - Discontinued Pipeline Products 74 Discontinued Pipeline Product Profiles 74 (libivirumab + exbivirumab) 74 ADL-100101 74 ADL-5747 74 ADL-5859 74 CB-182804 74 CB-183872 75 CB-625 75 ecallantide 75 loperamide hydrochloride 75 Marine Natural Products Program 75 Cubist Pharmaceuticals, Inc. - Company Statement 76 Cubist Pharmaceuticals, Inc. - Locations And Subsidiaries 78 Head Office 78 Other Locations & Subsidiaries 78 Appendix 80 Methodology 80 Coverage 80 Secondary Research 80 Primary Research 80 Expert Panel Validation 80 Contact Us 81 Disclaimer 81
List of Tables Cubist Pharmaceuticals, Inc., Key Information 6 Cubist Pharmaceuticals, Inc., Key Facts 6 Cubist Pharmaceuticals, Inc. - Pipeline by Indication, 2014 9 Cubist Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 11 Cubist Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 12 Cubist Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2014 13 Cubist Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014 14 Cubist Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 15 Cubist Pharmaceuticals, Inc. - Pre-Registration, 2014 16 Cubist Pharmaceuticals, Inc. - Phase III, 2014 17 Cubist Pharmaceuticals, Inc. - Phase II, 2014 18 Cubist Pharmaceuticals, Inc. - Phase I, 2014 19 Cubist Pharmaceuticals, Inc. - Preclinical, 2014 20 Cubist Pharmaceuticals, Inc. - Discovery, 2014 21 Cubist Pharmaceuticals, Inc. - Pipeline by Target, 2014 41 Cubist Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 42 Cubist Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 43 Cubist Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 45 Cubist Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 46 Cubist Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 73 Cubist Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 74 Cubist Pharmaceuticals, Inc., Subsidiaries 78
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
